Comparative Pharmacology
Head-to-head clinical analysis: HALOPERIDOL DECANOATE versus PROCHLORPERAZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALOPERIDOL DECANOATE versus PROCHLORPERAZINE.
HALOPERIDOL DECANOATE vs PROCHLORPERAZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Haloperidol decanoate is a long-acting ester prodrug of haloperidol, a typical antipsychotic. Haloperidol acts primarily as a dopamine D2 receptor antagonist in the central nervous system, particularly in the mesolimbic and mesocortical pathways. It also exhibits affinity for D1, D3, D4, sigma, and 5-HT2 receptors, but its antipsychotic efficacy is primarily attributed to D2 blockade.
Prochlorperazine is a phenothiazine antipsychotic that acts as a dopamine D2 receptor antagonist in the chemoreceptor trigger zone (CTZ) and at high doses in the mesolimbic system. It also has anticholinergic and antiemetic effects.
100-200 mg intramuscular deep injection every 4 weeks. Maximum 450 mg per month.
5-10 mg IM/IV every 3-4 hours as needed; or 5-10 mg PO 3-4 times daily; or 25 mg PR twice daily. Maximum IM/IV: 40 mg/day; PO: 40 mg/day.
None Documented
None Documented
Clinical Note
moderateProchlorperazine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fluticasone propionate."
Clinical Note
moderateProchlorperazine + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Prochlorperazine."
Clinical Note
moderateProchlorperazine + Methylphenidate
"The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methylphenidate."
Clinical Note
moderateTerminal elimination half-life of haloperidol decanoate: approximately 3 weeks (range 14-28 days) due to slow release from depot and subsequent de-esterification. Steady-state achieved after 3-4 monthly doses.
Terminal elimination half-life: 23-25 hours, with prolonged elimination in hepatic impairment.
Renal: 40% (as metabolites; <1% unchanged); Fecal: 60% (primarily via biliary elimination).
Renal: 70-80% (as metabolites), Fecal: 20-30% (unchanged and metabolites), Biliary: 10-15% of dose excreted in bile.
Category A/B
Category A/B
Typical Antipsychotic
Typical Antipsychotic / Antiemetic
Prochlorperazine + Quinagolide
"The therapeutic efficacy of Quinagolide can be decreased when used in combination with Prochlorperazine."